Physician profile
Christopher Peter Lucci
NPI 1447241955
$900,828.84
in general payments reported to CMS, 2019-2025
38 companies · $181K in 2025
The $181K reported for 2025 was more than what 99% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $83K · 2021: $107K · 2022: $166K · 2023: $110K · 2024: $132K · 2025: $181K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $314K · Travel and Lodging: $68K · Honoraria: $22K · Consulting Fee: $9,420 · Food and Beverage: $9,406 · Education: $74.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $314,041.61 |
| Travel and Lodging | $68,331.37 |
| Honoraria | $22,237.00 |
| Consulting Fee | $9,420.00 |
| Food and Beverage | $9,405.80 |
| Education | $74.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $444,810.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $315,469.00 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $119,575.79 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $9,102.85 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $8,113.63 | 2019-2024 | Farxiga, Breztri |
| Mannkind Corporation | $655.10 | 2023-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $521.13 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $308.26 | 2024-2025 | Recorlev |
| Lilly USA, LLC | $267.38 | 2020-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $199.55 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $197.88 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $190.20 | 2022 | |
| Amgen INC. | $177.85 | 2020-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $174.71 | 2022-2025 | |
| Dexcom, INC. | $128.05 | 2021-2023 | Dexcom G6 Transmitter |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $123.91 | 2024-2025 | Isturisa, Signifor Lar |
| Arbor Pharmaceuticals, INC. | $121.51 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Antares Pharma, INC. | $77.86 | 2019-2022 | |
| Amarin Pharma, INC. | $64.70 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.46 | 2019-2021 | |
| Abbott Laboratories | $47.67 | 2020 | |
| Sanofi-Aventis U.S. LLC | $37.34 | 2019 | |
| Nevro Corp. | $35.60 | 2022 | |
| Tactile Systems Technology INC | $31.27 | 2025 | Flexitouch Plus, Nimbl |
| Beta Bionics, INC. | $27.42 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Aytu Biopharma, INC. | $25.81 | 2020 | |
| Neurocrine Biosciences, INC. | $21.87 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.72 | 2020 | |
| Tolmar, INC. | $21.50 | 2025 | Jatenzo |
| Allergan, INC. | $19.94 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.93 | 2020 | |
| Sumitomo Pharma America, INC. | $19.32 | 2025 | Gemtesa |
| Radius Health, INC. | $18.91 | 2020 | |
| Amneal Pharmaceuticals LLC | $18.51 | 2025 | Unithroid |
| Idorsia Pharmaceuticals US INC | $16.58 | 2023 | Quviviq |
| Sequel Med Tech, LLC | $14.83 | 2025 | Twiist |
| Astellas Pharma US INC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.